Alnylam Pharmaceuticals stock sets HELIOS-B data for AHA and ISA

Published on 11/03/2026 at 22:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Alnylam Pharmaceuticals stock enters a catalyst-rich week as the company prepares HELIOS-B data. The findings will expand the clinical picture for AMVUTTRA in ATTR-CM.

HELIOS-B Data Set for Congresses

Alnylam will present long-term HELIOS-B findings at the American Heart Association Scientific Sessions and the International Symposium on Amyloidosis.
The company plans to highlight vutrisiran data covering cardiovascular outcomes, exercise capacity and neuropathy-related quality of life.
Upcoming presentations could add evidence for AMVUTTRA in transthyretin amyloidosis with cardiomyopathy.

Alnylam Pharmaceuticals, US02043Q1076, Illustration mit AI erstellt.

Alnylam Pharmaceuticals announced on Tuesday, November 3, 2026, that it will present new clinical and real-world data on AMVUTTRA (vutrisiran) at two medical meetings in November. The company said the presentations will add long-term evidence on RNAi-powered transthyretin, or TTR, silencing.

Alnylam Pharmaceuticals stock traded at 142.78 euros on Lang & Schwarz at 22:17 CET on Tuesday, November 3, 2026.

Long-Term HELIOS-B Results Ahead

According to the Alnylam Pharmaceuticals press release, a late-breaking presentation at the American Heart Association Scientific Sessions in Chicago will feature five-year HELIOS-B results, including two years of open-label extension data in patients with transthyretin amyloidosis with cardiomyopathy, or ATTR-CM. The AHA meeting runs from November 6 through November 9.

The company also plans to present an analysis of 48 HELIOS-B participants using cardiopulmonary exercise testing and imaging. Alnylam said the analysis found that vutrisiran preserved exercise capacity and cardiopulmonary performance over two years compared with placebo.

Further Data at ISA

At the International Symposium on Amyloidosis in Montevideo, Alnylam will present a post hoc analysis of neuropathy-related quality-of-life measures in patients with ATTR-CM and polyneuropathy. The company will also show real-world data from more than 1,000 patients starting vutrisiran and an indirect comparison of vutrisiran with acoramidis.

The presentations are relevant to investors because AMVUTTRA is approved in the United States for adults with ATTR-CM and for adults with hereditary transthyretin-mediated amyloidosis with polyneuropathy. In the HELIOS-B study, Alnylam said AMVUTTRA reduced the risk of all-cause mortality and recurrent cardiovascular events versus placebo through 36 months.

Investors can follow the real-time quote of Alnylam Pharmaceuticals stock on the market page.

US equities are also tracked through the S&P 500 market overview.

More news and analyses on Alnylam Pharmaceuticals stock are available on the company topic page.